Follow
Lori Friedman
Lori Friedman
ORIC Pharmaceuticals
Verified email at oricpharma.com
Title
Cited by
Cited by
Year
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
G Hatzivassiliou, K Song, I Yen, BJ Brandhuber, DJ Anderson, R Alvarado, ...
Nature 464 (7287), 431-435, 2010
18052010
Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941
TT Junttila, RW Akita, K Parsons, C Fields, GDL Phillips, LS Friedman, ...
Cancer cell 15 (5), 429-440, 2009
9662009
Systematic generation of high-resolution deletion coverage of the Drosophila melanogaster genome
AL Parks, KR Cook, M Belvin, NA Dompe, R Fawcett, K Huppert, LR Tan, ...
Nature genetics 36 (3), 288-292, 2004
8842004
The Identification of 2-(1H-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a Potent, Selective …
AJ Folkes, K Ahmadi, WK Alderton, S Alix, SJ Baker, G Box, ...
Journal of medicinal chemistry 51 (18), 5522-5532, 2008
8482008
Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families
LS Friedman, EA Ostermeyer, CI Szabo, P Dowd, ED Lynch, SE Rowell, ...
Nature genetics 8 (4), 399-404, 1994
8281994
Involvement of Brca2 in DNA repair
KJ Patel, PCC Veronica, H Lee, A Corcoran, FC Thistlethwaite, MJ Evans, ...
Molecular cell 1 (3), 347-357, 1998
8011998
A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene: implications for presymptomatic testing and screening
D Shattuck-Eidens, M McClure, J Simard, F Labrie, S Narod, F Couch, ...
Jama 273 (7), 535-541, 1995
5961995
In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models
KP Hoeflich, C O'Brien, Z Boyd, G Cavet, S Guerrero, K Jung, T Januario, ...
Clinical Cancer Research 15 (14), 4649-4664, 2009
5842009
Inactivation of PI (3) K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer
K Ali, DR Soond, R Pineiro, T Hagemann, W Pearce, EL Lim, H Bouabe, ...
Nature 510 (7505), 407-411, 2014
5332014
Akt inhibition promotes autophagy and sensitizes PTEN-null tumors to lysosomotropic agents
M Degtyarev, A De Mazière, C Orr, J Lin, BB Lee, JY Tien, WW Prior, ...
The Journal of cell biology 183 (1), 101-116, 2008
4882008
Drosophila p53 is a structural and functional homolog of the tumor suppressor p53
M Ollmann, LM Young, CJ Di Como, F Karim, M Belvin, S Robertson, ...
Cell 101 (1), 91-101, 2000
4802000
Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population.
LS Friedman, SA Gayther, T Kurosaki, D Gordon, B Noble, G Casey, ...
American journal of human genetics 60 (2), 313, 1997
3641997
Closing in on a breast cancer gene on chromosome 17q.
JM Hall, L Friedman, C Guenther, MK Lee, JL Weber, DM Black, MC King
American journal of human genetics 50 (6), 1235, 1992
3411992
Mechanism of MEK inhibition determines efficacy in mutant KRAS-versus BRAF-driven cancers
G Hatzivassiliou, JR Haling, H Chen, K Song, S Price, R Heald, ...
Nature 501 (7466), 232-236, 2013
3272013
Haplotype and phenotype analysis of six recurrent BRCA1 mutations in 61 families: results of an international study.
SL Neuhausen, S Mazoyer, L Friedman, M Stratton, K Offit, A Caligo, ...
American journal of human genetics 58 (2), 271, 1996
3121996
First-in-human phase I study of pictilisib (GDC-0941), a potent pan–class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors
D Sarker, JE Ang, R Baird, R Kristeleit, K Shah, V Moreno, PA Clarke, ...
Clinical cancer research 21 (1), 77-86, 2015
3112015
Predictive biomarkers of sensitivity to the phosphatidylinositol 3′ kinase inhibitor GDC-0941 in breast cancer preclinical models
C O'Brien, JJ Wallin, D Sampath, D GuhaThakurta, H Savage, ...
Clinical cancer research 16 (14), 3670-3683, 2010
3012010
Identifying genotype-dependent efficacy of single and combined PI3K-and MAPK-pathway inhibition in cancer
ML Sos, S Fischer, R Ullrich, M Peifer, JM Heuckmann, M Koker, ...
Proceedings of the National Academy of Sciences 106 (43), 18351-18356, 2009
2962009
GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway
JJ Wallin, KA Edgar, J Guan, M Berry, WW Prior, L Lee, JD Lesnick, ...
Molecular cancer therapeutics 10 (12), 2426-2436, 2011
2902011
Mutation Analysis of the BRCA1 Gene in Ovarian Cancers
H Takahashi, K Behbakht, PE McGovern, HC Chiu, FJ Couch, BL Weber, ...
Cancer research 55 (14), 2998-3002, 1995
2891995
The system can't perform the operation now. Try again later.
Articles 1–20